Overview Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction Status: Terminated Trial end date: 2007-11-01 Target enrollment: Participant gender: Summary This study assesses the safety and tolerability of RTA 402 in patients with liver disease. Phase: Phase 1/Phase 2 Details Lead Sponsor: Reata Pharmaceuticals, Inc.